Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH EBITDA Margin

EBITDA as a percentage of revenue.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 65.6%

EBITDA Margin was 65.6% in Q2 FY2026, up 25.4 pp from a year earlier. On a trailing-twelve-month basis it was 60.4%, up 27.2 pp year over year. Over 3 fiscal years it widened by 122.5 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 54.2% for the fiscal year ending Dec 2026, up from 45.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
65.6%+1.5 pp QoQ
Last fiscal yearDec 2025
45.1%+31.6 pp YoY
LTMJun 2026
60.4%+27.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+25.4 pp+1.7 pp-23.7 pp
1 year+31.6 pp+9.1 pp-22.6 pp
3 years+122.5 pp+8.6 pp-113.8 pp
5 years+22.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
45.1%
Year-over-year change
+31.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 EBITDA Margin of 60.4% is the highest of the 5 companies compared; the peer median is -2879.6%.
  • Its year-over-year change of +27.2 pp is the highest of 3, against a peer median of -2256.1 pp.
  • Over three fiscal years its change of +122.5 pp compares with a peer median of -540.2 pp.
AUPH Competitors Peer median
EBITDA Margin for AUPH and competitors
Company Period LTM level YoY 3-year change
AUPHAurinia Pharmaceuticals Inc.LTM Jun 202660.4% +27.2 pp+122.5 pp
EVMNEvommune, Inc.LTM Mar 2026-746.2% ——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-843.9% -542.0 pp-540.2 pp
ATTOAttovia Therapeutics, Inc.FY2025-4915.2% ——
ALMSAlumis Inc. Common StockLTM Jun 2026-5986.3% -3970.2 pp—
BHVNBiohaven Ltd.FY2025— ——
VERAVera Therapeutics, Inc.FY2025— ——
TRAXFirst Tracks Biotherapeutics IncFY2025— ——
MLTXMoonLake ImmunotherapeuticsFY2025— ——
ELDNEledon Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding AUPH) -2879.6%-2256.1 pp-540.2 pp

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.61M134.03M175.51M235.13M283.06M
Cost of Revenue1.09M5.66M14.15M28.25M32.67M
Gross Profit44.51M128.37M161.37M206.89M250.39M
Gross Margin97.6%95.8%91.9%88.0%88.5%
Research & Development51.14M44.99M49.64M20.79M32.51M
Selling, General & Admin171.44M196.37M195.04M172.03M101.79M
Operating Expenses225.25M239.84M253.06M211.57M145.48M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
EBITDA(177.45M)(103.65M)(63.05M)31.73M127.76M
EBITDA Margin-389.1%-77.3%-35.9%13.5%45.1%
Operating Income(180.74M)(111.47M)(91.69M)(4.69M)104.91M
Operating Margin-396.3%-83.2%-52.2%-2.0%37.1%
Interest Income529K5.12M17M16.97M13.57M
Interest Expense002.78M4.84M4.33M
Other Income / Expenses529K5.12M14.22M12.14M9.24M
Income Before Tax(180.21M)(106.35M)(77.47M)7.45M114.16M
Pre-Tax Margin-395.1%-79.3%-44.1%3.2%40.3%
Income Tax Expense760K1.83M551K1.7M(173.05M)
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Net Margin-396.8%-80.7%-44.5%2.4%101.5%
EPS (Basic)(1.40)(0.76)(0.54)0.042.14
EPS (Diluted)(1.40)(0.76)(0.54)0.042.07
Weighted Avg Shares129.37M141.92M143.24M143.06M134.37M
Weighted Avg Shares (Diluted)129.37M141.92M143.24M146.19M138.7M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.